BSEM BioStem Technologies, Inc.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.…
Industry Peers
BiotechnologyKey Statistics
About BioStem Technologies (NASDAQ: BSEM)
›
BioStem Technologies (NASDAQ: BSEM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 73 employees.
The shares were at 1.050 USD on 13 November 2026, down 77.4% over 52 weeks. Its 52-week range is 0.9000 USD to 8.400 USD: the price is 87.5% below the high and 16.7% above the low.
At a market capitalisation of 19.61M USD, it trades at 1.2 times trailing earnings and 3.6 times forward earnings. The median trailing P/E of its 14 largest Biotechnology peers is 35.0, a discount of 97% for BSEM.
BioStem Technologies reports return on equity of 78.0%, an operating margin of -67.5% and revenue down 27.9% year over year.
It holds more cash than debt, a net cash position of 5.74M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. The next earnings report is expected on 24 March 2027.